Preparing a Biopharma Company for Exit
Exit readiness in biopharma is not a checklist you complete in the months before a transaction. It is an operating posture that takes years to build — and a board discipline that is almost always started too late.
The companies that command premium valuations in acquisitions or licensing exits are not simply the ones with the best science. They are the ones that have organized their IP, their data, their regulatory correspondence, and their corporate structure in a way that makes the acquirer's diligence team confident rather than anxious. That confidence has a price. And its absence has one too.
This article addresses what boards and management teams need to do — and when — to position a biopharma company for a successful exit, whether that exit takes the form of an outright acquisition, a licensing transaction, or a strategic partnership with exit optionality built in.
The Exit Is Not an Event — It Is a Posture
The most common mistake biopharma boards make around exit planning is treating it as a project to be initiated when exit becomes imminent. The investment banker gets engaged, the data room gets assembled in a rush, the lawyers start reviewing contracts that have not been looked at in years. What follows is an expensive, stressful, and frequently value-destructive process of discovering problems that could have been addressed years earlier at a fraction of the cost.
Boards that govern well treat exit readiness as a continuous operating standard rather than a pre-transaction sprint. The question is not "are we ready to exit?" The question is "could we run a credible diligence process tomorrow if we needed to?" Companies that can answer yes command better terms, close faster, and avoid the valuation haircuts that accompany last-minute discovery.
This posture requires the board to hold management accountable not only for scientific and clinical progress but for the organizational hygiene that makes a transaction possible. That accountability needs to be explicit and ongoing — not assumed.
What Acquirers and Partners Are Actually Buying
Understanding what a strategic acquirer or licensing partner values makes it possible to work backward to what the company needs to demonstrate.
In an acquisition context, a large pharmaceutical company is buying one or more of the following: validated clinical assets with a clear regulatory pathway, a proprietary technology platform with multiple application possibilities, a team capable of advancing a pipeline, or the ability to block a competitor from accessing a space. The premium they pay is a function of how much conviction they have in each of these factors and how much risk they perceive in the assets they are acquiring.
In a licensing context, a partner is buying commercial rights to a defined asset or set of assets. They are assessing the quality of the underlying data, the robustness of the IP, the feasibility of the regulatory path, and the terms on which they can generate an acceptable return. Their diligence is narrower than an acquirer's, but no less rigorous within its scope.
In both cases, the acquirer or partner is pricing risk as much as they are pricing value. Every gap in the data package, every unresolved IP question, every ambiguous regulatory classification, and every poorly documented agreement adds to the risk premium they apply — and subtracts from what they are willing to pay.
The Four Domains of Exit Readiness
1. Intellectual Property
IP is the foundational asset in biopharma. It is also the area where diligence most frequently uncovers problems that derail or reprice transactions.
A board overseeing exit readiness needs to confirm that the patent portfolio is actively managed, with prosecution timelines tracked and expiry dates mapped to the commercial window of each asset. It needs to confirm that freedom-to-operate analyses have been conducted for lead programs and that any identified risks have been addressed or documented with appropriate counsel's assessment. It needs to confirm that all IP generated by employees, contractors, and academic collaborators has been properly assigned to the company — a deceptively simple requirement that is frequently incomplete in companies that have relied on university partnerships or engaged consultants informally.
The board does not need to understand patent law. It needs to ask management and outside counsel, at least annually, to certify that the portfolio is in order and that there are no unresolved ownership questions.
2. Regulatory Position
A company's regulatory posture is one of the first things a sophisticated acquirer evaluates. This includes not only the formal status of each program — IND in place, clinical hold history, meetings with FDA or EMA on record — but the quality and completeness of the company's regulatory correspondence file.
Companies that have maintained a clean, well-organized regulatory history — clear meeting minutes, complete CMC documentation, a defensible clinical development plan — significantly reduce the uncertainty a buyer must price into the transaction. Companies that have had informal conversations with regulators, operated on the basis of verbal guidance that was never confirmed in writing, or allowed their regulatory documentation to accumulate in inconsistent formats create diligence risk that translates directly into valuation risk.
Boards should confirm annually that regulatory documentation is current, organized, and centrally accessible. This is not a significant operational burden if it is maintained continuously. It is a significant problem if it is deferred.
3. Corporate and Contractual Structure
The corporate structure of an early-stage biopharma company often reflects the contingencies of its financing history more than any deliberate design. Entities may have been created in multiple jurisdictions for tax or historical reasons. Ownership of specific assets may sit in subsidiaries that are not fully integrated with the parent's cap table. Licensing agreements, collaboration agreements, and sponsored research agreements may contain assignment restrictions, change-of-control provisions, or milestone obligations that materially affect what an acquirer is actually buying.
These structural issues are not always problems — but they need to be understood and, where possible, rationalized before a transaction process begins. The worst time to discover that a material licensing agreement cannot be assigned without a third party's consent is during the final stages of a deal negotiation.
Boards should request a periodic structural review — ideally annually, and always before any formal transaction process — covering cap table, entity structure, and a summary of all material third-party agreements with particular attention to assignment, termination, and change-of-control provisions.
4. Data Integrity and Package Quality
In clinical-stage biopharma, the data package is the product. The quality of that package — its completeness, its organization, its analytical rigor, and the credibility of the institutions and investigators associated with it — directly determines whether a counterparty develops confidence or concern during diligence.
Boards should ask management, at least once per year, to walk through the data package for each material asset as if presenting it to a sophisticated acquirer. What story does the data tell? What gaps exist? What additional experiments or analyses would materially improve a counterparty's confidence? What would a skeptical diligence team challenge?
This exercise is valuable independent of any active transaction because it surfaces gaps early enough to address them through the normal course of research operations, rather than in a compressed timeline driven by transaction pressure.
Timing the Exit
Boards have an obligation to think carefully about when to initiate a transaction process, not only whether to pursue one.
The optimal timing for an exit is rarely obvious. In an ideal world, a company would transact at the moment when the data is sufficiently de-risked to support a strong valuation but before the additional clinical investment required for further de-risking consumes returns. In practice, this window is identified only in retrospect.
Several factors should inform the board's timing judgment. The first is cash runway — not because running out of cash should drive exit timing, but because the absence of financial pressure allows management to negotiate from strength rather than necessity. A company with 24 months of runway negotiates very differently than one with six. The second is competitive landscape — both the competitive dynamics in the therapeutic area and the consolidation activity among potential strategic acquirers, which can open or close windows for specific assets. The third is regulatory momentum — a company that has recently received positive FDA guidance, achieved a clinical milestone, or resolved a prior regulatory uncertainty is positioned to transact at the high point of that momentum rather than after it has been absorbed into market expectations.
The board's role is to engage with these timing questions actively rather than leaving them entirely to management's judgment. This does not mean second-guessing management on transaction strategy — it means ensuring that the question of timing is on the agenda, that the analysis is rigorous, and that the board's fiduciary perspective informs the decision.
Running a Competitive Process
When the decision to transact has been made, the governance of the process itself matters enormously.
A competitive process — one in which multiple potential counterparties are engaged simultaneously — almost always produces better outcomes than a bilateral negotiation. The leverage that comes from a credible alternative is real, and it is difficult to manufacture after the fact. Boards should push management to run competitive processes even when there is a preferred partner, and should be skeptical of management's preference for exclusive negotiations without a compelling strategic rationale.
The board's role in a transaction process is to provide oversight and judgment, not to manage the process directly. This means reviewing and approving the outreach list, the non-disclosure agreements, the information shared at each stage, and the final term sheet or letter of intent. It means engaging independent financial advisors when the transaction is material enough to warrant it. And it means preserving the board's ability to say no — maintaining genuine optionality rather than allowing momentum and sunk cost to drive the company toward a transaction it should not complete.
The Board's Role When a Deal Is on the Table
When a specific transaction is presented to the board for approval, the governance obligation crystallizes into a set of specific questions.
Is the consideration fair, both in its structure and in the context of comparable transactions? Has an independent financial opinion been obtained where appropriate? Have all material risks and contingencies been disclosed? Are the representations and warranties the company is making accurate and defensible? What is the plan if the transaction does not close?
On the last question: boards should always ask management to articulate what happens if the deal falls through. A board that has thought through this scenario — and has confirmed that the company has adequate runway and strategic alternatives to survive it — is in a far stronger negotiating position than one that has allowed itself to become dependent on a specific outcome.
Exit Readiness as a Governance Standard
The underlying principle is straightforward: a board that takes exit readiness seriously is a board that is doing its job. It is creating the conditions under which the company can realize the value of its science on the best possible terms — which is the fundamental fiduciary obligation that board membership in a biopharma company entails.
The specific mechanisms — the annual IP review, the data package walk-through, the structural audit, the ongoing conversation about timing — are not onerous if they are maintained continuously. They become onerous only when they are neglected and must be reconstructed under pressure.
The companies that exit well are the ones that prepared to exit long before they knew they were going to.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing and exit transactions across pharmaceutical and advanced materials sectors.